# Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by Paracetamol as Measured by Functional Magnetic Resonance Imaging (fMRI) in Subjects With Osteoarthritis (OA)

> **NCT01105936** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 31 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** Paracetamol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01105936
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-01
- **Primary completion:** 2011-08-01
- **Final completion:** 2011-08-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01105936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01105936, "Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by Paracetamol as Measured by Functional Magnetic Resonance Imaging (fMRI) in Subjects With Osteoarthritis (OA)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01105936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*